Clinical trials: Disease;Neurological
Diabetic Neuropathies, Diabetes Mellitus, Type 2
A Study To Evaluate The Effect Of Topiramate On Clinical And Electrophysiological Parameters In Subjects With Diabetic Peripheral Polyneuropathy
The purpose of the study is to evaluate the effect of topiramate on clinical and electrophysiological parameters in patients with diabetic peripheral polyneuropathy.
- Conditions
- Diabetic Neuropathies, Diabetes Mellitus, Type 2, Polyneuropathies
- Trial name
- NCT00231673
- Testing
- Topiramate
- Volunteers
- 72 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Ischemic Stroke
Effectiveness and Safety Trial of a New Ischemic Stroke Treatment Within 24 Hours From Stroke Onset (NEST-2)
The purpose of this pivotal study is to demonstrate safety and effectiveness of the NeuroThera® Laser System (referred to hereafter as NTS) in the treatment of Subjects diagnosed with acute ischemic stroke.
- Trial name
- NCT00419705
- Testing
- NeuroThera® Laser System
- Where
- 58 sites in United States, Germany and 2 more
- Volunteers
- 660 people
- Sponsor
- PhotoThera, Inc
Chronic Ischemic Stroke
Study of Modified Stem Cells (SB623) in Patients With Chronic Motor Deficit From Ischemic Stroke
Controlled study of stereotactic, intracranial injection of SB623 cells in patients with fixed motor deficits from ischemic stroke
- Trial name
- ACTIsSIMA (NCT02448641)
- Testing
- SB623 Implant (2.5M), SB623 Implant (5.0M)
- Where
- 65 sites in United States
- Volunteers
- 163 people
- Sponsor
- SanBio, Inc.
Amyotrophic Lateral Sclerosis
Evaluate the Safety of Neuronata-R® Inj. Suspended With HypoTHermosol® FRS (HTS-FRS) in Patients With ALS
This clinical trial is a single-center, open-label, and phase I clinical trial to Evaluate the Safety of Neuronata-R® Inj. suspended with HypoTHermosol® FRS (HTS-FRS) in Patients with Amyotrophic Lateral Sclerosis.
- Trial name
- NCT06676423
- Testing
- Lenzumestrocel, Riluzole
- Where
- South Korea
- Volunteers
- 8 people
- Sponsor
- Corestemchemon, Inc.
Alzheimer's Disease
Efficacy, Safety and Tolerability of Tideglusib to Treat Mild-to-Moderate Alzheimer's Disease Patients
The main purpose of this study is to evaluate the cognitive changes after administration of tideglusib versus placebo at two oral doses and two treatment regimes for 26 weeks in patients with mild to moderate Alzheimer's disease.
- Trial name
- ARGO (NCT01350362)
- Testing
- tideglusib
- Where
- 6 sites in Belgium, Finland and 4 more
- Volunteers
- 306 people
- Sponsor
- Noscira SA
Painful Diabetic Neuropathy
Efficacy and Safety of Eslicarbazepine Acetate as Therapy for Patients With Painful Diabetic Neuropathy
The primary objective of the study is to assess the efficacy of eslicarbazepine acetate (ESL) as therapy for patients with painful diabetic neuropathy.
- Trial name
- NCT00980746
- Testing
- Eslicarbazepine acetate
- Volunteers
- 557 people
- Sponsor
- Bial - Portela C S.A.
Gastrointestinal Dysfunction, Malnutrition
Postoperative GI Dysfunction and Nutrition in Malnourished Cancer Surgery Patients
This is a prospective two-center observational cohort study in adult patients undergoing major abdominal and/or pelvic oncologic surgery with pre-existing malnutrition.
- Conditions
- Gastrointestinal Dysfunction, Malnutrition, Delirium - Postoperative, Abdominal Neoplasm
- Trial name
- GIDNUT (NCT07622888)
- Testing
- Serotonin (e.g., serotonin adipinate), Standard Prokinetic Therapy (excluding serotonin)
- Where
- Russia
- Volunteers
- 120 people
- Sponsor
- Arma Ltd.
Pain, Bone Neoplasm
A Study to Assess the Efficacy of Intravenous Bondronat (Ibandronate) in Patients With Malignant and Painful Bone Disease
This 2 arm study will compare the efficacy of intravenous Bondronat with that of zoledronic acid in patients with malignant bone disease experiencing moderate to severe pain.
- Conditions
- Pain, Bone Neoplasm, Neoplasm Metastasis
- Trial name
- NCT00099203
- Testing
- ibandronate [Bondronat], zoledronic acid
- Where
- 72 sites in United States, Argentina and 16 more
- Volunteers
- 163 people
- Sponsor
- Hoffmann-La Roche
Visual Impairment, Macular Edema
Efficacy and Safety of Ranibizumab Intravitreal Injections Versus Dexamethasone Intravitreal Implant in Patients With Central Retinal Vein Occlusion (CRVO)
This clinical trial is designed to compare ranibizumab in comparison with Dexamethasone implant® after 6 months of treatment. In the study arm Lucentis will be given monthly in a pro re nata scheme whereas the comparator…
- Conditions
- Visual Impairment, Macular Edema, Central Retinal Vein Occlusion
- Trial name
- COMRADE-C (NCT01396083)
- Testing
- Ranibizumab
- Where
- 64 sites in Germany, Hungary and 2 more
- Volunteers
- 243 people
- Sponsor
- Novartis Pharmaceuticals
Growth Hormone Deficiency, Turner Syndrome
Evaluation of Convenience and Compliance of the Easypod™ Electronic Self-injector
This is an international, multicenter study involving children treated with Saizen®, a growth hormone, who will be trained to use easypod, a new electronic injector and will complete a questionnaire after 12 week of use.
- Conditions
- Growth Hormone Deficiency, Turner Syndrome, Chronic Renal Failure, Small for Gestational Age
- Trial name
- NCT00738205
- Volunteers
- 834 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Sleep Apnea, Obstructive
SensAwake™ Sleep Quality Trial
The SensAwake™ modification to the Fisher and Paykel automatically titrating positive airway pressure (APAP) device aims to sense whether the patient is awake via respiratory patterns that differentiate between sleep and wake.
- Trial name
- SASQT (NCT00811213)
- Testing
- SleepStyle 200 Auto Series with SensAwake, SleepStyle 200 Auto Series with out SensAwake
- Where
- Australia
- Volunteers
- 45 people
- Sponsor
- Fisher and Paykel Healthcare
Cerebral Apoplexy
Single-dose Incremental Intravenous Injection of SY-007 in Healthy Subjects
This study is a single-dose incremental, randomized, double-blind, parallel, placebo-controlled study on safety, tolerance and pharmacokinetics healthy subjects.
- Trial name
- NCT04111523
- Testing
- SY-007
- Where
- China
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- Suzhou Yabao Pharmaceutical R&D Co., Ltd.
Parkinson Disease
Low-dose Carbon Monoxide (HBI-002) Trial to Evaluate Safety, Tolerability, PK, and Biomarkers in Parkinson's Disease
A phase 2a multicenter, randomized, double-blind, placebo-controlled multiple dose study to evaluate the safety, tolerability, pharmacokinetics, of HBI-002, an oral low-dose carbon monoxide (CO) liquid drug product, administered…
- Trial name
- LoCaMoTE-PD (NCT07005180)
- Testing
- HBI-002
- Where
- 8 sites in United States
- Volunteers
- 36 people
- Sponsor
- Hillhurst Biopharmaceuticals, Inc.
Non-Arteritic Anterior Ischemic Optic Neuropathy
Efficacy and Safety of Intranasal Cenegermin in Adult Participants With Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION)
This is a phase 3, randomized, multicenter, vehicle-controlled, double-masked study to evaluate the efficacy and safety of intranasal cenegermin compared with vehicle control in adult participants with NAION.
- Trial name
- NCT07453888
- Testing
- Cenegermin, Vehicle
- Where
- 38 sites in United States, Australia and 2 more
- Volunteers
- 272 people
- Sponsor
- Dompé Farmaceutici S.p.A
Stable Angina, Unstable Angina
Optical Coherence Tomography Comparison of Neointimal Coverage Between CRE8 DES and BMS
The purpose of the study is to demonstrate the non-inferiority of Cre8 (CID) Drug Eluting Stent, studied 3 months after implant, compared to Vision/Multilink8 Bare Metal Stent (Abbott) studied at 1 month, in terms of neointimal…
- Conditions
- Stable Angina, Unstable Angina, NSTEMI
- Trial name
- DEMONSTRATE (NCT01543373)
- Testing
- Amphilimus Eluting Stent, Bare Metal Stent
- Where
- 6 sites in Italy, Netherlands
- Volunteers
- 38 people
- Sponsor
- CID - Carbostent & Implantable Devices
Sleep Apnea, Obstructive, Hypopnea Syndrome
Treatment of Refractory Excessive Daytime Sleepiness in Patients With Obstructive Sleep Apnea/Hypopnea Syndrome (OSA/HS) Using Nasal Continuous Positive Airway Pressure (nCPAP) Therapy (0249-015)
The purpose of this study is to determine the safety and efficacy of MK0249 in treating refractory excessive daytime sleepiness (EDS) in patients with Obstructive Sleep Apnea/Hypopnea Syndrome (OSA/HS) using nasal continuous…
- Conditions
- Sleep Apnea, Obstructive, Hypopnea Syndrome, Excessive Daytime Sleepiness
- Trial name
- NCT00620659
- Testing
- Comparator: MK0249, Comparator: modafinil
- Volunteers
- 125 people
- Sponsor
- Merck Sharp & Dohme LLC
Hypoxic-Ischemic Encephalopathy, Bronchopulmonary Dysplasia
Efficacy Evaluation of UCB-MNCs in the Treatment of Refractory Neonatal Diseases
Hypoxic-ischemic encephalopathy (HIE), bronchopulmonary dysplasia (BPD), short bowel syndrome (SBS) are refractory in clinical treatment.
- Conditions
- Hypoxic-Ischemic Encephalopathy, Bronchopulmonary Dysplasia, Short Bowel Syndrome
- Trial name
- NCT06427642
- Testing
- Mononuclear cells, Mild hypothermia therapy, Breathing support technique
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Shandong Qilu Stem Cells Engineering Co., Ltd.
Migraine
Study of Oral Atogepant Tablets to Assess Change in Disease Activity in Adult Japanese Participants With Episodic Migraine
A migraine is a moderate to severe headache on one side of the head. A migraine attack is a headache that may be accompanied by throbbing, nausea, vomiting, sensitivity to light and sound, or other symptoms.
- Trial name
- JPN PIVOTAL (NCT05861427)
- Testing
- Atogepant
- Where
- 48 sites in Japan
- Volunteers
- 524 people
- Sponsor
- AbbVie
Multiple System Atrophy
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ION464 Administered to Adults With Multiple System Atrophy (HORIZON)
The primary objectives are to evaluate the safety and tolerability of multiple doses of ION464 administered via intrathecal (IT) injection (Part 1) and to evaluate the long-term safety and tolerability of ION464 (Part 2) in…
- Trial name
- HORIZON (NCT04165486)
- Testing
- ION464
- Where
- 15 sites in Austria, France and 3 more
- Volunteers
- 40 people
- Sponsor
- Ionis Pharmaceuticals, Inc.
Cerebrovascular Accident
Headache Study to Compare Aggrenox Full Dose and Reduced Dose
Tolerability of a four weeks treatment with Aggrenox® modified release capsules b.i.d, compared to reduced dose during the first two weeks of treatment in a double-blind, randomized controlled parallel group comparison trial…
- Trial name
- NCT00274586
- Testing
- Aggrenox® modified release capsules
- Where
- Taiwan
- Volunteers
- 100 people
- Sponsor
- Boehringer Ingelheim
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.